Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials

Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2019
This article has no abstract
Epistemonikos ID: 33cbd784e097fe9f29a9a11e97b4b59a1c7b3523
First added on: Feb 11, 2025